Response to beta interferon 1b among Saudi patients with multiple sclerosis

Area of Science:

• Neurology
• Immunology

Background:

• Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
• Relapsing-remitting MS (R-R MS) is the most common form, characterized by unpredictable relapses.
• Beta interferons are disease-modifying therapies used in MS treatment.

Purpose of the Study:

• To evaluate the efficacy and tolerability of subcutaneous beta interferon 1b (B1F1b) in Saudi patients diagnosed with R-R MS.
• To assess the impact of B1F1b on relapse rates, disability progression, and patient safety.

Main Methods:

• An open-label study conducted in Riyadh, Saudi Arabia, from 1997 to 2001.
• Thirty-two R-R MS patients under 50 years old with mild to moderate disability received subcutaneous B1F1b (8 million IU) three times weekly.
• Primary outcomes included relapse rate reduction and time to first relapse; secondary outcomes assessed disability progression, tolerability, and safety.

Main Results:

• Twenty-eight patients completed the study; 32.5% were relapse-free, and 37.5% experienced a reduction in relapses.
• No patients showed progression of disability (P<0.0249).
• Adverse reactions were generally mild, with influenza-like symptoms (53.6%) and injection-site reactions (35.7%) being most common.

Conclusions:

• Subcutaneous B1F1b demonstrates efficacy in Saudi R-R MS patients, notably in reducing relapse rates and potentially preventing disability.
• The treatment is well-tolerated, with manageable side effects.
• Further long-term studies are warranted to fully ascertain B1F1b's role in preventing long-term disability progression.